AstraZeneca to disclose compensation to U.S. doctors

AstraZeneca to disclose compensation to U.S. doctors

May 21, 2009 - Wilmington, DE - AstraZeneca (NYSE:AZN) today announced it will begin reporting compensation to healthcare professionals who speak on behalf of our company and products in the United States starting in 2010. This is the latest in a series of initiatives to enhance AstraZeneca's openness with the public.  

AstraZeneca will report compensation to healthcare professionals biannually beginning in 2010, with the first report being posted to in August 2010 for the first six months of 2010. This report will disclose compensation to all practicing healthcare professionals speaking on behalf of AstraZeneca.

"AstraZeneca believes it is important to be open about how we conduct our business and how we help people through our medicines and programs," said Rich Fante, US President, AstraZeneca Pharmaceuticals LP.  "In particular, we want the public to better understand how we partner with healthcare professionals to benefit patients."

AstraZeneca is proud that it improves patient health by helping ensure healthcare professionals are knowledgeable about our products and patient assistance programs, and by providing healthcare professionals with timely, relevant information that enables them to make the best treatment decisions for their patients.

AstraZeneca knows that in order to make a meaningful difference to patient health, it is important to be open about how we conduct our business. AstraZeneca builds on the transparency efforts it launched in March 2008. AstraZeneca previously announced it will publicly share additional or enhanced information about its policy positions, political contributions, medical education grants, contributions to nonprofit organizations, post-marketing study commitments, its compliance program and clinical trials on its Web site.

To learn more about AstraZeneca and its efforts, please visit

About AstraZeneca
AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with global healthcare sales of $ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion dollar healthcare business.

For more information about AstraZeneca in the US or our AZ&MeTM Prescription Savings programs, please visit:

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.